Efficacy and safety of sodium oxybate in alcohol‐dependent patients with a very high drinking risk level
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Medication development for alcohol relapse prevention or reduction of consumption is highly challenging due to methodological issues of pharmacotherapy trials. Existing approved medications are only modestly effective with many patients failing to benefit from these therapies. Therefore, there is a pressing need for other effective treatments with a different mechanism of action, especially for patients with very high (VH) drinking risk levels (DRL) because this is the most severely affected population of alcohol use disorder patients. Life expectancy of alcohol‐dependent patients with a VH DRL is reduced by 22 years compared with the general population and approximately 90 000 alcohol‐dependent subjects with a VH DRL die prematurely each year in the EU (Rehm et al. ). A promising new medication for this population is sodium oxybate, a compound that acts on GABA B receptors and extrasynaptic GABA A receptors resulting in alcohol‐mimetic effects. In this article, a European expert group of alcohol researchers and clinicians summarizes data (a) from published trials, (b) from two new—as yet unpublished—large clinical trials (GATE 2 (n = 314) and SMO032 (n = 496), (c) from post hoc subgroup analyses of patients with different WHO‐defined DRLs and (d) from multiple meta‐analyses. These data provide convergent evidence that sodium oxybate is effective especially in a subgroup of alcohol‐dependent patients with VH DRLs. Depending on the study, abstinence rates are increased up to 34 percent compared with placebo with risk ratios up to 6.8 in favor of sodium oxybate treatment. These convergent data are supported by the clinical use of sodium oxybate in Austria and Italy for more than 25 years. Sodium oxybate is the sodium salt of γ‐hydroxybutyric acid that is also used as a recreational (street) drug suggestive of abuse potential. However, a pharmacovigilance database of more than 260 000 alcohol‐dependent patients treated with sodium oxybate reported very few adverse side effects and only few cases of abuse. We therefore conclude that sodium oxybate is an effective, well‐tolerated and safe treatment for withdrawal and relapse prevention treatment, especially in alcohol‐dependent patients with VH DRL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wood, A. M., Kaptoge, S., Butterworth, A. S., Willeit, P., Warnakula, S., Bolton, T., Paige, E., Paul, D. S., Sweeting, M., Burgess, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30134-x · Cited by 1,188 · cited 1×
“Drug development for alcohol dependence is highly challenging (Litten et al. 2012; Litten et al. 2018) due to methodological issues of alcohol pharmacotherapy trials (Litten et al. 2012; Yardley & Ray 2017).”
BackgroundJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1163 · Cited by 594
Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis
Skinner, M. D., Lahmek, P., Pham, H., & Aubin, H.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087366 · Cited by 347
Self-citationGamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses
Leone, M. A., Vigna-Taglianti, F., Avanzi, G., Brambilla, R., & Faggiano, F. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006266.pub2 · Cited by 163
Umhau, J. C., Momenan, R., Schwandt, M. L., Singley, E., Lifshitz, M., Doty, L., Adams, L. J., Vengeliene, V., Spanagel, R., Zhang, Y., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.125 · Cited by 144
Self-citationRoerecke, M., Gual, A., & Rehm, J. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08379 · Cited by 100
Self-citationReduced Drinking in Alcohol Dependence Treatment, What Is the Evidence?
Mann, K., Aubin, H.-J., & Witkiewitz, K. (2017) · European Addiction Research · doi:10.1159/000481348 · Cited by 93 · cited 1×
“In line with these results, a 12-month open comparative study in 86 patients with a VH DRL at baseline showed that sodium oxybate, administered at a dose of 50 mg/kg/day, had a higher abstinence rate (65 percent) than naltrexone 50mg/day (49 percent) (Nava et al. 2006).”
ResultSelf-citationCaputo, F., Skala, K., Mirijello, A., Ferrulli, A., Walter, H., Lesch, O., & Addolorato, G. (2014) · CNS Drugs · doi:10.1007/s40263-014-0183-1 · Cited by 34
Self-citation
Cited by
Improving translation of animal models of addiction and relapse by reverse translation
Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“SMO craving and abuse potential may limit its use; however, at therapeutic doses, SMO abuse seems to be a relatively infrequent phenomenon among patients without psychiatric comorbidities or poly-drug use [96, 100, 105].”
BackgroundSpanagel, R. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/rspanagel · Cited by 127
Self-citationOff-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
Guiraud, J., Addolorato, G., Aubin, H.-J., Batel, P., de Bejczy, A., Caputo, F., Goudriaan, A. E., Gual, A., Lesch, O., Maremmani, I., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.003 · Cited by 20
Self-citation
Metadata
- Authors
- van den Brink, W., Addolorato, G., Aubin, H., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O., Mann, K., Maremmani, I., Nutt, D., Paille, F., Perney, P., Rehm, J., Reynaud, M., Simon, N., Söderpalm, B., Sommer, W. H., Walter, H., & Spanagel, R.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2018-07
- Volume
- 23
- Issue
- 4
- Pages
- 969-986
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2884345621
- Cited by
- 75
- References
- 9
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of sodium oxybate in alcohol‐dependent patients with a very high drinking risk level. https://app.cochat.ai/papers/10.1111/adb.12645
- The paper
- van den Brink, W., Addolorato, G., Aubin, H., Benyamina, A., Caputo, F., Dematteis, M., Gual, A., Lesch, O., Mann, K., Maremmani, I., Nutt, D., Paille, F., Perney, P., Rehm, J., Reynaud, M., Simon, N., Söderpalm, B., Sommer, W. H., Walter, H., & Spanagel, R. (2018). Efficacy and safety of sodium oxybate in alcohol‐dependent patients with a very high drinking risk level. Addiction Biology. https://doi.org/10.1111/adb.12645
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.